Arsenic trioxide and the phosphoinositide 3-kinase/Akt pathway in chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4311-4312

  Goussetis, Dennis J ^a,b   Platanias, Leonidas C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Jesse Brown Veterans Health Administration Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; LEUKEMIA CELL; LYMPHOCYTE; NOTE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, BIOLOGICAL; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77956256946     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1496     Document Type: Note

References (12)

1. 2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 2010;16:4382-91.
2. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
3. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009;284:18583-7.
4. Davison K, Mann KK, Waxman S, Miller WH, Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103:3496-502.
5. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
6. Yoon P, Giafis N, Smith J, et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCRABL- expressing cells. Mol Cancer Ther 2006;5:2815-23.
7. Altman JK, Yoon P, Katsoulidis E, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2008;283:1992-2001.
8. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/ refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-7.
9. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009;88: 221-7.
10. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Rev. Epub 2010 May 14.
11. Giafis N, Katsoulidis E, Sassano A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006;66:6763-71.
12. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006;107:4549-53.